PT - JOURNAL ARTICLE AU - Sender, Ron AU - Bar-On, Yinon M. AU - Flamholz, Avi AU - Gleizer, Shmuel AU - Bernsthein, Biana AU - Phillips, Rob AU - Milo, Ron TI - The total number and mass of SARS-CoV-2 virions in an infected person AID - 10.1101/2020.11.16.20232009 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.16.20232009 4099 - http://medrxiv.org/content/early/2020/11/17/2020.11.16.20232009.short 4100 - http://medrxiv.org/content/early/2020/11/17/2020.11.16.20232009.full AB - Quantitatively describing the time course of the SARS-CoV-2 infection within an infected individual is important for understanding the current global pandemic and possible ways to combat it. Here we integrate the best current knowledge about the abundance of potential SARS-CoV-2 host cells and typical concentrations of virions in bodily fluids to estimate the total number and mass of SARS-CoV-2 virions in an infected person. We estimate that each infected person carries 109-1011 virions during peak infection, with a total mass of about 1 μg-0.1 mg, which curiously implies that all SARS-CoV-2 virions currently in the world have a mass of only 0.1-1 kg. Knowledge of the absolute number of virions in an infected individual can put into perspective parameters of the immune system response, minimal infectious doses and limits of detection in testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the European Research Council (Project NOVCARBFIX 646827), Israel Science Foundation (Grant 740/16), Beck-Canadian Center for Alternative Energy Research, Dana and Yossie Hollander, Ullmann Family Foundation, Helmsley Charitable Foundation, Larson Charitable Foundation, Wolfson Family Charitable Trust, Charles Rothschild, Selmo Nussenbaum, Miel de Botton (R.M.), the National Institutes of Health (1R35 GM118043-01 (Maximizing Investigators Research Award)) (R.P.) the Israeli Council for Higher Education (CHE) via the Weizmann Data Science Research Center and by a research grant from Madame Olga Klein - Astrachan (R.S.). R.M. is the Charles and Louise Gartner Professional Chair. Y.M.B. is an Azrieli Fellow Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTo generate our estimates of cellular turnover, we extracted values from the literature as detailed in the spreadsheet files available as supplementary information